Mutations in KRAS and NRAS are present in approximately 40% and 30% of MM patients, respectively, often coinciding with BRAF mutations at a rate of around 10%, underscoring the significance of the MAPK signaling pathway [18,21]. The gene discussed is KRAS; the disease is Miyoshi myopathy.